-
公开(公告)号：US11723912B2
公开(公告)日：2023-08-15
申请号：US16467945
申请日：2017-12-08
Applicant: University of Utah Research Foundation
Inventor： Stefan M. Pulst , Daniel R. Scoles , Sharan Paul
IPC: C07H21/02 , C07H21/04 , A61K31/713 , A61K45/06 , C12N15/113 , A61P25/28
CPC classification number: A61K31/713 , A61K45/06 , A61P25/28 , C12N15/113 , C12N2310/14
Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.
-
公开(公告)号：US20240392290A1
公开(公告)日：2024-11-28
申请号：US18623472
申请日：2024-04-01
Applicant: University of Utah Research Foundation
Inventor： Stefan M. Pulst , Daniel R. Scoles , Sharan Paul
IPC: C12N15/113 , A61K45/06
Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.
-
公开(公告)号：US20140170752A1
公开(公告)日：2014-06-19
申请号：US13975004
申请日：2013-08-23
Applicant: University of Utah Research Foundation
Inventor： Stefan M. Pulst , Sharan Paul , Warunee Dansithong
CPC classification number: C12N15/86 , C12N5/0619 , C12N5/0696 , C12N15/85 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2510/00 , C12N2710/10043 , C12N2710/10343
Abstract: Systems, constructs, and methods for reprogramming cells are provided. In one aspect, for example, a transformation construct for generating iPS cells can include an expression vector having a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter.
Abstract translation: 提供了用于重新编程细胞的系统，构建体和方法。 在一个方面，例如，用于产生iPS细胞的转化构建体可以包括具有多个重编程因子的表达载体，每个重编程因子都由单独的启动子控制。
-
公开(公告)号：US20240180953A1
公开(公告)日：2024-06-06
申请号：US18204383
申请日：2023-05-31
Applicant: University of Utah Research Foundation
Inventor： Stefan M. Pulst , Daniel R. Scoles , Sharan Paul
IPC: A61K31/713 , A61K45/06 , A61P25/28 , C12N15/113
CPC classification number: A61K31/713 , A61K45/06 , A61P25/28 , C12N15/113 , C12N2310/14
Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.
-
公开(公告)号：US20210238590A1
公开(公告)日：2021-08-05
申请号：US15734174
申请日：2019-06-14
Applicant: University of Utah Research Foundation
Inventor： Stefan M. Pulst , Daniel R. Scoles , Sharan Paul
IPC: C12N15/113 , A61K45/06
Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.
-
Patent Agency Ranking
公开(公告)号：US10533178B2
公开(公告)日：2020-01-14
申请号：US15973088
申请日：2018-05-07
Inventor： C. Frank Bennett , Susan M. Freier , Stefan M. Pulst , Daniel R. Scoles , Gene Hung
IPC: C12N15/113 , A61K48/00 , C12N5/00
Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.
-
公开(公告)号：US20170175113A1
公开(公告)日：2017-06-22
申请号：US15127352
申请日：2015-03-19
Inventor： C. Frank Bennett , Susan M. Freier , Stefan M. Pulst , Daniel R. Scoles , Gene Hung
IPC: C12N15/113
CPC classification number: C12N15/113 , C12N2310/11 , C12N2310/14 , C12N2310/141 , C12N2310/315 , C12N2310/317 , C12N2310/321 , C12N2310/323 , C12N2310/3231 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/3525
Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism. Provided are methods for reducing expression of Ataxin 2 (ATXN2) mRNA and protein in an animal. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases, including spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism by inhibiting expression of Ataxin 2 in an animal.
-
公开(公告)号：US20160222411A1
公开(公告)日：2016-08-04
申请号：US14984861
申请日：2015-12-30
Applicant: University of Utah Research Foundation
Inventor： Stefan M. Pulst , Sharan Paul , Warunee Dansithong
IPC: C12N15/86 , C12N5/0793 , C12N5/074 , C12N15/85
CPC classification number: C12N15/86 , C12N5/0619 , C12N5/0696 , C12N15/85 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2510/00 , C12N2710/10043 , C12N2710/10343
Abstract: Systems, constructs, and methods for reprogramming cells are provided. In one aspect, for example, a transformation construct for generating iPS cells can include an expression vector having a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter.
Abstract translation: 提供了用于重新编程细胞的系统，构建体和方法。 在一个方面，例如，用于产生iPS细胞的转化构建体可以包括具有多个重编程因子的表达载体，每个重编程因子都由单独的启动子控制。
-
公开(公告)号：US20200069721A1
公开(公告)日：2020-03-05
申请号：US16467945
申请日：2017-12-08
Applicant: University of Utah Research Foundation
Inventor： Stefan M. Pulst , Daniel R. Scoles , Sharan Paul
IPC: A61K31/713 , A61K45/06 , A61P25/28 , C12N15/113
Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1 -regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.
-
公开(公告)号：US10006027B2
公开(公告)日：2018-06-26
申请号：US15127352
申请日：2015-03-19
Inventor： C. Frank Bennett , Susan M. Freier , Stefan M. Pulst , Daniel R. Scoles , Gene Hung
IPC: C07H21/02 , C07H21/04 , A61K31/70 , C12N15/113
CPC classification number: C12N15/113 , C12N2310/11 , C12N2310/14 , C12N2310/141 , C12N2310/315 , C12N2310/317 , C12N2310/321 , C12N2310/323 , C12N2310/3231 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/3525
Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism. Provided are methods for reducing expression of Ataxin 2 (ATXN2) mRNA and protein in an animal. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases, including spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism by inhibiting expression of Ataxin 2 in an animal.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.023 seconds)
